Sugi Predict

Sugi Predict / Compounds / SCHEMBL700531

SCHEMBL700531

SCHEMBL700531

N[C@@H]1CCc2[nH]c3ccccc3c2C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NR2E1 Q9Y466 1/20 1.00
▸ HTR6 P50406 1/20 0.60
▸ HTR1B P28222 4/20 0.59
▸ HTR1D P28221 3/20 0.59
▸ HTR2A P28223 1/20 0.51
▸ HTR2C P28335 1/20 0.51
▸ TP53 P04637 1/20 0.50
▸ HPGD P15428 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ SSTR3 P32745 1/20 0.49
▸ KCNH2 Q12809 1/20 0.49
▸ TAAR1 Q96RJ0 1/20 0.49
▸ RB1 P06400 2/20 0.48
▸ EGFR P00533 1/20 0.47
▸ IGF1R P08069 1/20 0.47
▸ FLT4 P35916 1/20 0.47
▸ KDR P35968 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL833503 1.00 NR2E1 (1.00) NR2E1HTR6HTR1BHTR1DHTR2A
SCHEMBL29670383 1.00 NR2E1 (1.00) NR2E1HTR6HTR1BHTR1DHTR2A
SCHEMBL834930 1.00 NR2E1 (1.00) NR2E1HTR6HTR1BHTR1DHTR2A
Hydrochloric Acid SCHEMBL7412638 0.98 NR2E1 (0.97) NR2E1HTR6HTR1BHTR1DHTR2A
SCHEMBL29991655 0.88 NR2E1 (0.79) NR2E1HTR6HTR1BHTR1DHTR2A
SCHEMBL29992005 0.88 NR2E1 (0.79) NR2E1HTR6HTR1BHTR1DHTR2A
SCHEMBL6533665 0.88 NR2E1 (0.79) NR2E1HTR6HTR1BHTR1DHTR2A
SCHEMBL4905673 0.88 NR2E1 (0.79) NR2E1HTR6HTR1BHTR1DHTR2A
Hydrochloric Acid SCHEMBL11283863 0.87 NR2E1 (0.77) NR2E1HTR6HTR1BHTR1DHTR2A
SCHEMBL8702813 0.87 NR2E1 (0.75) NR2E1HTR6HTR1BHTR1DHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-216778796-U Cyclization device for producing (R) -3-amino-1, 2,3, 4-tetrahydrocarbazole 福建福瑞明德药业有限公司 2022-06-21 — — CN claimed
CN-104402798-B A kind of 3-amino-1, the method for splitting of 2,3,4-tetrahydro carbazoles 杭州瑞德化工有限公司 2016-09-14 — — CN claimed
CN-104402798-A Resolution method for 3-amino-1, 2, 3, 4-tetrahydrocarbazole HANGZHOU READ CHEMICAL CO LTD 2015-03-11 — — CN claimed
EP-4710923-A2 INDOLE AHR INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2026-03-18 — — EP disclosed
EP-3612030-B1 INDOLE AHR INHIBITORS AND USES THEREOF IKENA ONCOLOGY INC (US) 2025-12-24 — — EP disclosed
US-20250276975-A1 POLYMORPHIC COMPOUNDS AND USES THEREOF PAHR THERAPEUTICS, INC. 2025-09-04 — — US disclosed
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2025-04-17 — — US disclosed
EP-4529955-A2 POLYMORPHIC CARBAZOLE DERIVATIVES AND USES THEREOF Ikena Oncology, Inc. (US) 2025-04-02 — — EP disclosed
EP-4065582-B1 POLYMORPHIC CARBAZOLE DERIVATIVES AND USES THEREOF IKENA ONCOLOGY INC (US) 2025-02-19 — — EP disclosed
US-12162884-B2 Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[1,5-a] [1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine as aryl hydrocarbon receptor (AHR) inhibitors Ikena Oncology, Inc. (US) 2024-12-10 — — US disclosed
US-12077542-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2024-09-03 — — US disclosed
US-20090258922-A1 COMPOUND EXHIBITING PGD2 RECEPTOR ANTAGONIST SHIONOGI & CO., LTD. 2009-10-15 — — US disclosed
US-20090258922-A1 COMPOUND EXHIBITING PGD2 RECEPTOR ANTAGONIST SHIONOGI & CO., LTD. 2009-10-15 — — US disclosed
US-20090258922-A1 COMPOUND EXHIBITING PGD2 RECEPTOR ANTAGONIST SHIONOGI & CO., LTD. 2009-10-15 — — US disclosed
US-7534897-B2 Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism SHIONOGI & CO., LTD. (JP) 2009-05-19 — — US disclosed
US-7534897-B2 Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism SHIONOGI & CO., LTD. (JP) 2009-05-19 — — US disclosed
US-7534897-B2 Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism SHIONOGI & CO., LTD. (JP) 2009-05-19 — — US disclosed
US-20050171143-A1 Compound exhibiting pgd 2 receptor antagonism SHIONOGI & CO., LTD. (JP) 2005-08-04 — — US disclosed
WO-2005033099-A2 NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS; PROCESSES FOR THEIR PREPARATION AND COMPOSITIONS THEREOF GLENMARK PHARMACEUTICALS LTD. (US) 2005-04-14 — — WO disclosed
EP-1505061-A1 COMPOUND EXHIBITING PGD 2 RECEPTOR ANTAGONISM SHIONOGI & CO., LTD. (JP) 2005-02-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258922-A1 COMPOUND EXHIBITING PGD2 RECEPTOR ANTAGONIST CYSLTR2, CYSLTR1, HRH2 NR2E1 100/4885HTR6 409/4885HTR1B 185/4885
US-12162884-B2 Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[1,5-a] [1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine as aryl hydrocarbon receptor (AHR) inhibitors AHR, ARNT, FFAR1 NR2E1 105/4885HTR6 240/4885HTR1B 91/4885
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 NR2E1 391/4885HTR6 39/4885HTR1B 76/4885
US-20250276975-A1 POLYMORPHIC COMPOUNDS AND USES THEREOF AHR, ARNT, MTNR1B NR2E1 229/4885HTR6 425/4885HTR1B 192/4885
US-20050171143-A1 Compound exhibiting pgd 2 receptor antagonism CYSLTR2, CYSLTR1, HRH2 NR2E1 92/4885HTR6 404/4885HTR1B 279/4885
US-12077542-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 NR2E1 391/4885HTR6 39/4885HTR1B 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.